MHRA approves expansion of ModiFY trial; Modi-1 to be assessed in RCC in combination with double CPIs May 31, 2024
5 patients deaths reported the next day after update provided on Interim TAMARACK Ph 2 Study Data May 15, 2024
FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer May 15, 2024
First Patient Dosed in trial Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC May 7, 2024
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer May 7, 2024
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk NMIBC May 7, 2024
Ph 2 data for ERLEADA + ADT after radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than 2 years post-surgery May 7, 2024
Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk NMIBC Announced May 7, 2024
$15 million CIRM Grant Supports the Ongoing Ph 1 TRAVERSE Trial of ALLO-316 in Patients with Advanced or Metastatic RCC May 1, 2024
First Cohort Completed and Second Cohort of Ph 1/2 Study of INKmune™ NK Cell Therapy in Patients with Metastatic CRPC Initiated May 1, 2024
CHMP Adopts Positive Opinion Recommending Approval of Opdivo in Combination with Cisplatin and Gemcitabine for the 1L Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma May 1, 2024
XTANDI (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting May 1, 2024
Arvinas and Novartis to Develop and Commercialize PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer April 16, 2024
Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN (nadofaragene firadenovec-vncg) in 2 Patient Cohorts April 16, 2024
Alliance A032103 (MODERN) Randomized, Ph 2/3 Adjuvant Trial in Urothelial Cancer announced April 9, 2024
Positive Surveillance Analysis from the Randomized Ph 3 IMvigor011 Trial in MIBC announced April 8, 2024
Pluvicto® pre-taxane label expansion filing planned in H2 2024 based on latest data from Ph 3 PSMAfore study April 8, 2024
China’s NMPA Accepts Supplemental BLA for enfortumab vedotin with KEYTRUDA for 1L Bladder Cancer April 2, 2024
Positive CHMP Opinion Received for XTANDI in Additional Recurrent Early Prostate Cancer Treatment Setting March 26, 2024
Rolling NDA submitted to the FDA for UGN-102; 12-month duration of response data from ENVISION expected to support completion of NDA submission March 19, 2024
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies March 12, 2024
